Please login to the form below

Not currently logged in
Email:
Password:

Penn Pharma appoints Carlo Truppi to drive US business

He joins the manufacturing firm from Bilcare Global Clinical Supplies

Penn Pharma has appointed Carlo Truppi as US business development manager to lead efforts into increasing its business from US companies.

The UK-based provider of pharmaceutical development and manufacturing services said Truppi's work would mainly involve working with pharma companies operating in the east coast of North America to boost business at Penn's newly launched manufacturing site in south Wales, UK.

Truppi has more than a decade's experience in pharmaceutical services, and was most recently director of business development at Bilcare Global Clinical Supplies.

He said: “The investment we are making is set to catapult Penn into new markets by providing key players in the industry with a specialist technology led contained facility in which to manufacture highly potent drugs. I am delighted at the prospect of being at the forefront of these discussions.”

Penn's chief executive Dr Richard Yarwood said: “Carlo is going to play a pivotal role in finding business for our recently constructed contained manufacturing operation, which is due to open in Q1 2013. His broad experience in the industry will be invaluable to us as we grow our capability in processing highly potent drug products.''

1st November 2012

From: Sales

Share

Tags

PMEA Awards 2020

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
JPA Health

JPA Health is an award-winning public relations, marketing and advocacy firm known for sharing our clients’ commitment to making people...

Latest intelligence

What’s in it for me? How to engage, motivate and support staff with internal training at OPEN Health
...
Environmental impact of in-person vs. virtual meetings
Although it will be tempting to resume in-person activities in the same capacity as before, we need to weigh the pros and cons of virtual vs. in-person vs. hybrid events...
US biosimilars
The US celebrates five years of biosimilars on the market – a look to the past, present and future
Why the success of biosimilars in the US has been mixed...

Infographics